Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to Minimize Adverse Effects and Use of Healthcare Resources

References

• Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis – a quiet revolution. Nat Rev Neurol. 2015;11:134–142. doi:10.1038/nrneurol.2015.14
   PubMed Web of Science ®Google Scholar
• Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31:752–759. doi:10.1097/WCO.0000000000000622
   PubMed Web of Science ®Google Scholar
• Perez-Carmona N, Fernandez-Jover E, Sempere AP. [Epidemiology of multiple sclerosis in Spain]. Rev Neurol. 2019;69:32–38. doi:10.33588/rn.6901.2018477
   Web of Science ®Google Scholar
• Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol. 2004;61:1613–1615. doi:10.1001/archneur.61.10.1613
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545–558. doi:10.1038/nri3871
   PubMed Web of Science ®Google Scholar
• Dobson R, Giovannoni G. Multiple sclerosis – a review. European J Neurol. 2019;26:27–40. doi:10.1111/ene.13819
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. Curr Opin Neurol. 2018;31:233–243. doi:10.1097/WCO.0000000000000561
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518. doi:10.1136/bmj.i3518
   PubMed Web of Science ®Google Scholar
• Torkildsen O, Myhr KM, Bo L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. European J Neurol. 2016;23(Suppl 1):18–27. doi:10.1111/ene.12883
   PubMed Web of Science ®Google Scholar
• Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep. 2011;11:492–497. doi:10.1007/s11910-011-0216-9
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659–674. doi:10.1007/s40265-014-0212-x
   PubMed Web of Science ®Google Scholar
• Diebold M, Sievers C, Bantug G, et al. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. J Autoimmun. 2018;86:39–50. doi:10.1016/j.jaut.2017.09.009
   PubMed Web of Science ®Google Scholar
• Juanatey A, Blanco-Garcia L, Tellez N. Ocrelizumab: its efficacy and safety in multiple sclerosis. Rev Neurol. 2018;66:423–433.
   PubMed Web of Science ®Google Scholar
• Derfuss T, Mehling M, Papadopoulou A, et al. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020;19:336–347. doi:10.1016/S1474-4422(19)30391-6
   PubMed Web of Science ®Google Scholar
• Naismith RT, Wundes A, Ziemssen T, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020;34:185–196. doi:10.1007/s40263-020-00700-0
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–788. doi:10.1212/WNL.0000000000005347
   PubMed Web of Science ®Google Scholar
• Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96–120. doi:10.1177/1352458517751049
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678–692. doi:10.1093/brain/awq386
   PubMed Web of Science ®Google Scholar
• Albrecht P, Bouchachia I, Goebels N, et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation. 2012;9:163. doi:10.1186/1742-2094-9-163
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled Phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–1107. doi:10.1056/NEJMoa1114287
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–1097. doi:10.1056/NEJMoa1206328
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23:253–265. doi:10.1177/1352458516649037
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Phillips JT, et al. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. Neurol Ther. 2016;5:45–57. doi:10.1007/s40120-016-0042-8
   Google Scholar
• Havrdova E, Giovannoni G, Gold R, et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol. 2017;24:726–733. doi:10.1111/ene.13272
   PubMed Web of Science ®Google Scholar
• Boster A, Nicholas J, Wu N, et al. Comparative effectiveness research of disease-modifying therapies for the management of multiple sclerosis: analysis of a large health insurance claims database. Neurol Ther. 2017;6:91–102. doi:10.1007/s40120-017-0064-x
   PubMed Web of Science ®Google Scholar
• Braune S, Grimm S, van Hovell P, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol. 2018;265:2980–2992. doi:10.1007/s00415-018-9083-5
   PubMed Web of Science ®Google Scholar
• Rock M, Pike J, Jones E, et al. Reduced healthcare resource utilisation for patients treated with delayed release dimethyl fumarate versus injectable therapies: findings from a real-world cross-sectional study of MS patients. Value Health. 2018;21:S342. doi:10.1016/j.jval.2018.09.2045
   Web of Science ®Google Scholar
• Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:458–468. doi:10.1136/jnnp-2018-319831
   PubMed Web of Science ®Google Scholar
• Dello Russo C, Scott KA, Pirmohamed M. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature. Pharmacol Ther. 2020;107710. doi:10.1016/j.pharmthera.2020.107710
   Web of Science ®Google Scholar
• Theodore Phillips J, Erwin AA, Agrella S, et al. Consensus management of gastrointestinal events associated with delayed-release dimethyl fumarate: a delphi study. Neurol Ther. 2015;4:137–146. doi:10.1007/s40120-015-0037-x
   Google Scholar
• Laplaud DA, Casey R, Barbin L, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93:e635–e646. doi:10.1212/WNL.0000000000007938
   PubMed Web of Science ®Google Scholar
• Sabin J, Urtiaga S, Pilo B, et al. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. J Neurol. 2020;267:2362–2371. doi:10.1007/s00415-020-09848-7
   Web of Science ®Google Scholar
• Pandey K, Giles K, Balashov K. Safety and effectiveness of delayed-release dimethyl fumarate maintained over 4 years in multiple sclerosis patients treated in routine medical practice. Paper presented at: 35th Congress of the European Committee for Treatment & Research in Multiple Sclerosis ECTRIMS 2019; Stockholm, Sweden.
   Google Scholar
• Fox EJ, Vasquez A, Grainger W, et al. Gastrointestinal tolerability of delayed-release dimethyl fumarate in a multicenter, open-label study of patients with relapsing forms of multiple sclerosis (MANAGE). Int J MS Care. 2016;18:9–18. doi:10.7224/1537-2073.2014-101
   PubMedGoogle Scholar
• Pandey K, Giles K, Jacques F, et al. Remaining on dimethyl fumarate for 3 months is associated with high rates of long-term treatment continuation in the clinical setting. Paper presented at: Consortium of Multiple Sclerosis Centers 2019; Seattle, WA
   Google Scholar
• Min J, Cohan S, Alvarez E, et al. Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes. Neurol Ther. 2019;8:109–119. doi:10.1007/s40120-019-0127-2
   Web of Science ®Google Scholar
• Sejbaek T, Nybo M, Petersen T, Illes Z. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42–46. doi:10.1016/j.msard.2018.05.007
   PubMed Web of Science ®Google Scholar
• Ernst FR, Barr P, Elmor R, Wong SL. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study. Curr Med Res Opin. 2017;33:2099–2106. doi:10.1080/03007995.2017.1380616
   PubMed Web of Science ®Google Scholar
• Mallucci G, Annovazzi P, Miante S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265:1850–1859. doi:10.1007/s00415-018-8916-6
   PubMed Web of Science ®Google Scholar
• Allan M, Grant L. A retrospective analysis of real-world discontinuation rates with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis. Neurol Ther. 2020;9:85–92. doi:10.1007/s40120-019-00174-3
   Web of Science ®Google Scholar
• Narapureddy B, Dubey D. Clinical evaluation of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis: efficacy, safety, patient experience and adherence. Patient Prefer Adherence. 2019;13:1655–1666. doi:10.2147/PPA.S187529
   PubMed Web of Science ®Google Scholar
• Tan H, Cai Q, Agarwal S, et al. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28:51–61. doi:10.1007/s12325-010-0093-7
   PubMed Web of Science ®Google Scholar
• Maia C, Costa A, Abreu P, Sa MJ. All-cause hospitalizations in multiple sclerosis patients. Rev Neurol. 2019;68:229–235. doi:10.33588/rn.6806.2018281
   Web of Science ®Google Scholar
• Fox RJ, Chan A, Gold R, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6:220–229. doi:10.1212/CPJ.0000000000000238
   PubMedGoogle Scholar
• Mehta D, Miller C, Arnold DL, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. Neurology. 2019;92:e1724–e1738. doi:10.1212/WNL.0000000000007262
   PubMed Web of Science ®Google Scholar
• Sainz de la Maza S, Medina S, Villarrubia N, et al. Factors associated with dimethyl fumarate-induced lymphopenia. J Neurol Sci. 2019;398:4–8. doi:10.1016/j.jns.2019.01.007
   PubMed Web of Science ®Google Scholar
• Chan A, Rose J, Alvarez E, et al. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract. 2020. doi:10.1212/CPJ.0000000000000800
   Google Scholar
• Longbrake EE, Naismith RT, Parks BJ. et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin;2015. 1. doi: 10.1177/2055217315596994
   Google Scholar
• Briner M, Bagnoud M, Miclea A, et al. Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age. Ther Adv Neurol Disord. 2019;12:1756286419843450. doi:10.1177/1756286419843450
   Web of Science ®Google Scholar
• Mao-Draayer Y, Giles K, Balashov K. Safety and effectiveness of delayed-release dimethyl fumarate in patients ≥ 55 years enrolled in the phase IV ESTEEM study Paper presented at: Consortium of Multiple Sclerosis Centers 2019; Seattle, WA.
   Google Scholar